Clinical Trials in Biopharma
- Eric K. Steffe
- Life Sciences Intellectual Property Review 2011
According to a recent study, biotechnology companies and universities discovered 42 percent of all innovative drugs approved by the FDA between 1998 and 2007. Biotechnology companies, however, are unprepared for the intellectual property issues that arise as a promising drug progresses through clinical trials. Eric Steffe explains. To view the full article, download the attached PDF.